- Home
- APD vs MRNA Comparison
APD vs MRNA Comparison
Compare APD & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | APD | MRNA |
|---|---|---|
| Founded | 1940 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.3B | 61.6B |
| IPO Year | 1994 | 2018 |
Fundamental Metrics
Financial Performance| Metric | APD | MRNA |
|---|---|---|
| Price | $314.19 | $221.22 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 23 | 23 |
| Target Price | ★ $342.55 | $138.37 |
| AVG Volume (30 Days) | 892.0K | ★ 16.9M |
| Earning Date | 11-05-2026 | 11-06-2026 |
| Dividend Yield | ★ 2.32% | N/A |
| EPS Growth | N/A | ★ 21.77 |
| EPS | ★ N/A | N/A |
| Revenue | $12,037,300,000.00 | ★ $19,263,000,000.00 |
| Revenue This Year | $6.06 | $8.13 |
| Revenue Next Year | $5.70 | $16.26 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 4.29 |
| 52 Week Low | $229.11 | $22.28 |
| 52 Week High | $314.87 | $254.48 |
Technical Indicators
Market Signals| Indicator | APD | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 74.14 | 56.30 |
| Support Level | $289.62 | $45.39 |
| Resistance Level | N/A | $254.48 |
| Average True Range (ATR) | 4.69 | 22.75 |
| MACD | 2.03 | -3.28 |
| Stochastic Oscillator | 94.15 | 53.57 |
Price Performance
Historical ComparisonAbout APD Air Products and Chemicals Inc.
Since its founding in 1940, Air Products has become one of the leading industrial gas suppliers globally, with operations in 50 countries and 19,000 employees. The company is the world's largest supplier of hydrogen and helium. It has a unique portfolio serving customers across industries, including chemicals, energy, healthcare, metals, and electronics. Air Products generated roughly $12 billion in revenue in fiscal 2025.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.